FDMT (4D Molecular Therapeutics) Notes Receivable: $0.00 Mil (As of Mar. 2026)


FDMT 4D Molecular Therapeutics Inc FDMT
55 GF Score
Price $11.60
GF Value $214.49
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is 4D Molecular Therapeutics Notes Receivable?

4D Molecular Therapeutics FDMT +0.69% 55 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates FDMT with a GF Score™ of 55/100 and a GF Value™ of $214.49 (Possible Value Trap). The stock has 6 warning signs investors should review.

4D Molecular Therapeutics's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

4D Molecular Therapeutics Notes Receivable Related Terms

4D Molecular Therapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for 4D Molecular Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4D Molecular Therapeutics Notes Receivable Chart

4D Molecular Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

4D Molecular Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FDMT
55GF Score
4D Molecular Therapeutics Inc FDMT
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4D Molecular Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
4D Molecular Therapeutics (FDMT) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on 4D Molecular Therapeutics and its competitors.
Is 4D Molecular Therapeutics' Notes Receivable too high?
4D Molecular Therapeutics' current Notes Receivable is $0.00 Mil. Overall, 4D Molecular Therapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4D Molecular Therapeutics' Notes Receivable compare to KYTX and XOMA?
4D Molecular Therapeutics' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on 4D Molecular Therapeutics and its competitors. 4D Molecular Therapeutics's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4D Molecular Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, 4D Molecular Therapeutics (FDMT) is currently considered Possible Value Trap. The stock's GF Value™ is $214.49, compared to a current price of $11.60 — trading 94.6% below its estimated fair value. The current Notes Receivable is $0.00 Mil. 4D Molecular Therapeutics' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For 4D Molecular Therapeutics (FDMT), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?

Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued. The current stock price of $11.60 is trading 94.6% below its estimated GF Value™ of $214.49. GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.

Key valuation signals for FDMT:

  • Notes Receivable: $0.00 Mil
  • GF Value™: $214.49 vs. price of $11.60 (94.6% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4D Molecular Therapeutics Business Description

Address 5858 Horton Street, Suite 455, Emeryville, CA, USA, 94608
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
55GF Score

Get the complete analysis for FDMT

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.60
Price
$214.49
GF Value